endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

R&D channel feed

Up­dat­ed: No­var­tis dis­con­tin­ues lead Gy­ro­scope gene ther­a­py af­ter $800M+ buy­out

Last year
Cell/Gene Tx

Gilead, As­traZeneca/Dai­ichi Sankyo of­fer first look at TROP2 AD­Cs in first-line lung can­cer as ri­val­ry heats up 

Last year

Cri­net­ics re­veals pos­i­tive topline pri­ma­ry and sec­ondary end­point da­ta in PhI­II acromegaly tri­al

Last year

As­traZeneca's Tagris­so/chemo com­bo staves off lung can­cer for al­most nine months. But will side ef­fects lim­it its use?

Last year

MIT sci­en­tists look to un­lock po­ten­tial of ‘self-ad­ju­vant­i­ng’ mR­NA vac­cines in mice

Last year
Pharma

Can No­vo Nordisk's block­buster weight loss drug and oth­er GLP-1s al­so work in NASH? The an­swer is com­pli­cat­ed

Last year
Pharma
In Focus

Al­ny­lam, Roche’s RNAi can­di­date scores mid-stage win in hy­per­ten­sion

Last year

Val­ne­va and Pfiz­er tout re­sults for the PhII of its Ly­me dis­ease vac­cine

Last year

CymaBay meets pri­ma­ry, key sec­ondary end­points in PhI­II liv­er tri­al

Last year

J&J shut­ters PhI­II tri­al for pul­monary hy­per­ten­sion drug, block­ing its ex­pand­ed use as patent ex­piry looms

Last year
Pharma

Astel­las pulls law­suit over price ne­go­ti­a­tions as Xtan­di side­steps first list of 10 drugs

Last year

Janssen looks to turn PhI­II win for Ry­bre­vant in EGFR-mu­tat­ed NSCLC in­to pres­sure on As­traZeneca block­buster

Last year
Pharma

Bio­gen names Jane Gro­gan head of re­search af­ter split­ting R&D

Last year
People

Mod­er­na touts broad­er an­ti­body da­ta on up­dat­ed Covid vac­cine as it gears up for fall roll­out

Last year
Coronavirus

Bio­Car­dia un­veils in­ter­im da­ta that led it to stop PhI­II en­roll­ment of heart fail­ure stem cell ther­a­py

Last year
Cell/Gene Tx

Ole­ma On­col­o­gy re­ceives $180M in to­tal fund­ing

Last year
Financing

Tiv­dak gets pri­ma­ry end­point in PhI­II con­fir­ma­to­ry study

Last year

Beam dos­es first pa­tient with base-edit­ed cell ther­a­py

Last year
Cell/Gene Tx

First RNA edit­ing ther­a­py nears clin­ic, as Wave ask reg­u­la­tors to green­light hu­man tests

Last year

Bay­er ex­pands Keren­dia heart fail­ure pro­gram to 15,000 pa­tients as it plans to start three Phase III tri­als

Last year
Pharma

Roche says Ale­cen­sa helps keep ALK-pos­i­tive lung can­cer at bay af­ter surgery as it looks to ex­pand la­bel

Last year

BioN­Tech, Du­al­i­ty­Bio steer ADC in­to PhI­II, with aim to com­pete in HER2-low sub­group with En­her­tu

Last year

Bavar­i­an Nordic aban­dons Covid boost­er af­ter da­ta show it's not as ef­fec­tive against new vari­ants

Last year
Coronavirus

Zevra beefs up rare dis­ease port­fo­lio via $91M ac­qui­si­tion of Ac­er Ther­a­peu­tics

Last year
Deals
First page Previous page 72737475767778 Next page Last page
A service from the Financial Times